MOTS - Motus GI Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.3300
-0.3700 (-10.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.7000
Open3.8000
Bid3.3100 x 4000
Ask3.8500 x 1200
Day's Range3.3004 - 3.8000
52 Week Range2.3400 - 10.6600
Volume74,371
Avg. Volume58,680
Market Cap71.431M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2280
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.90
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Motus GI Presents Positive Clinical Results from REDUCE Study Evaluating Pure-Vu® System in Hospitalized Colonoscopy Patients at Digestive Disease Week® 2019

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced it will present positive full clinical results from the Company’s REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study evaluating the Pure-Vu® System at Digestive Disease Week® 2019 (“DDW”).

  • Business Wire8 days ago

    Motus GI to Present at the 20th Annual B. Riley FBR Investor Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will present a company overview and update at the 20th Annual B. Riley FBR Investor Conference on Wednesday, May 22, 2019 at 4:30 PM PT in Beverly Hills, CA. A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.motusgi.com.

  • How Much Are Motus GI Holdings, Inc. (NASDAQ:MOTS) Insiders Spending On Buying Shares?
    Simply Wall St.8 days ago

    How Much Are Motus GI Holdings, Inc. (NASDAQ:MOTS) Insiders Spending On Buying Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Business Wire13 days ago

    Motus GI Reports First Quarter 2019 Financial Results and Provides Corporate Update

    – Full clinical results of REDUCE Study to be presented at Digestive Disease Week® 2019

  • Business Wire24 days ago

    Motus GI to Present Clinical Results from REDUCE Study Evaluating the Pure-Vu® System at Digestive Disease Week® 2019

    Motus GI Holdings, Inc. (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that full clinical results from the Company’s REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study evaluating the Pure-Vu® System will be presented at Digestive Disease Week® 2019 (“DDW”), being held May 18 - 21, 2019 in San Diego, CA. The data being presented at DDW is embargoed until the time of presentation.

  • Business Wire2 months ago

    Motus GI Reports Full Year 2018 Financial Results and Provides Business Outlook

    – 2018 marked by strengthening of executive team, expansion of commercial organization, bolstering of clinical and health economic data, and achievement of important regulatory mil

  • Business Wire2 months ago

    Motus GI Expands Intellectual Property Portfolio with Issuance of New U.S. Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,179,202 titled, “Systems and methods for cleaning body cavities and for endoscopic steering,” which protects the Company’s flagship product, the Pure-Vu® System.

  • Business Wire2 months ago

    Motus GI to Present at the Oppenheimer 29th Annual Healthcare Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will present a company overview and update at Oppenheimer’s 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 2:45 PM ET in New York, NY. A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.motusgi.com.

  • Business Wire3 months ago

    Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “An intra-procedural endoscopic cleansing device for achieving adequate colon preparation in poorly prepped patients,” has been published in the peer-reviewed Journal of Clinical Gastroenterology.

  • Business Wire5 months ago

    Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Endoscopy Journal

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “A novel device for intra-colonoscopy cleansing of inadequately prepared colonoscopy patients – a feasibility study,” has been published in the peer-reviewed journal, Endoscopy.

  • Business Wire5 months ago

    Motus GI to Present at Biotech Showcase™ 2019

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced that Tim Moran, Chief Executive Officer, will present a company overview and update at Biotech Showcase™ on Tuesday, January 8, 2019 at 4:00 PM PST in San Francisco, CA. In addition to the presentation, management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. A live audio webcast of the presentation will be accessible on the Events page of the Investor section on the Company’s website at www.motusgi.com.

  • Business Wire5 months ago

     Motus GI Announces $13.5 Million Follow-on Public Offering

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the pricing of its follow-on public offering of 5,000,000 shares of its common stock at a price of $2.70 per share, for total gross proceeds of $13.5 million. In addition, the Company granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock at the public offering price. Piper Jaffray & Co. is acting as the sole book-running manager for the offering.

  • Business Wire5 months ago

    Motus GI Announces Launch of Proposed Follow-on Public Offering

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed follow-on public offering of 5,000,000 shares of its common stock. In addition, the Company intends to grant the underwriters a 30-day option to purchase an additional 750,000 shares of common stock.

  • What Kind Of Shareholder Appears On The Motus GI Holdings Inc’s (NASDAQ:MOTS) Shareholder Register?
    Simply Wall St.6 months ago

    What Kind Of Shareholder Appears On The Motus GI Holdings Inc’s (NASDAQ:MOTS) Shareholder Register?

    A look at the shareholders of Motus GI Holdings Inc (NASDAQ:MOTS) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see Read More...

  • Business Wire6 months ago

    Motus GI to Present at the Piper Jaffray Healthcare Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will provide a corporate overview during a fireside chat at the Piper Jaffray Healthcare Conference on Thursday, November 29, 2018 at 10:00 a.m. EST in New York, NY.

  • GlobeNewswire6 months ago

    Orchestra BioMed™ Announces Completion of $41 Million Financing

    Capital proceeds to support late-stage clinical development of lead cardiovascular product candidates for artery disease and hypertension        Financing structure provides.

  • Business Wire6 months ago

    Motus GI Reports 2018 Third Quarter Financial Results and Provides Business Update

    Third quarter featured strengthening of executive team with proven commercial leadership, building additional clinical and health economic evidence demonstrating potential value of

  • Business Wire6 months ago

    Motus GI Announces Successful Clinical Use of Pure-Vu® Slim Sleeve with Slim Colonoscopes

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the first successful clinical cases were completed in late October with the Company’s Pure-Vu® Slim Sleeve, a compatible extension to the Pure-Vu® System for slim colonoscopes. The Company recently announced that the Pure-Vu® Slim Sleeve had received special 510(k) clearance from the U.S. Food and Drug Administration (FDA).

  • Business Wire7 months ago

    Motus GI Presents Positive Clinical Data from U.S. Prospective Study of the Pure-Vu® System at the 2018 American College of Gastroenterology (ACG) Annual Meeting

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that it presented positive clinical data at the ACG 2018 Annual Meeting being held October 5-10, 2018 in Philadelphia, PA.

  • Business Wire8 months ago

    Motus GI to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Mark Pomeranz, President and COO of Motus GI, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 3:00 p.m. EDT in New York, NY. As part of his presentation, Mr. Pomeranz will provide a corporate overview, along with an update on the current pre-launch, market development activities and ongoing REDUCE clinical study of the Company's flagship product, the Pure-Vu® System.

  • Business Wire8 months ago

    Motus GI Appoints Medical Device Commercial Leader Timothy P. Moran as Chief Executive Officer; Mark Pomeranz Continues in Key Executive Leadership Role as President and Chief Operating Officer

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Timothy P. Moran will assume the role of Chief Executive Officer and member of the Board of Directors on October 1, 2018. Mr. Moran will join Motus GI from ConvaTec Group Plc (CTEC.L) where he has served as President of the Americas since 2015.

  • Is Motus GI Holdings Inc’s (NASDAQ:MOTS) Balance Sheet A Threat To Its Future?
    Simply Wall St.8 months ago

    Is Motus GI Holdings Inc’s (NASDAQ:MOTS) Balance Sheet A Threat To Its Future?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Motus GI Holdings Inc (NASDAQ:MOTS), as the company does not have to adhere to strict debt covenants. However, it alsoRead More...

  • Business Wire8 months ago

    Motus GI Receives FDA Clearance to Market Pure-Vu® Slim Sleeve for Use with Slim Colonoscopes

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that it has received special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Pure-Vu® Slim Sleeve, a compatible extension to the Pure-Vu® System for slim colonoscopes.